MOESM1 of Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
The ATLAS bioassay was developed to empirically identify neoantigens by expressing each unique patient-specific tumor mutation individually in E. coli, pulsing autologous dendritic cells in an ordered
Structure of 2Q1-Fab, an antibody selective for IDH2R140Q-HLA-B*07:02 Descriptor: 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, CHLORIDE ION, DI(HYDROXYETHYL)ETHER, ... Authors: Mi
Table S1. Mutation profiles of BLS genes in colorectal, melanoma, gastric, and uterine cancers. Table S2. Ď (dN/dS ratio) and neutrality tests for selection signal of neoantigen carrying genes in BLS
Background: Messenger ribonucleic acid (mRNA) vaccine has been considered as a potential therapeutic strategy and the next research hotspot, but their efficacy against prostate adenocarcinoma (PRAD) r
